Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-067 + Teclistamab in R/R Multiple Myeloma
NCT06588660Phase 1Terminated
- Sponsor
- University of Washington
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vevoctadekin in multiple myeloma (MM), sponsored by University of Washington. Primary endpoints: Monotherapy dose-limiting toxicities (DLT) rates at 28 days, Combination therapy DLT rates at 28 days and 2 more. Started Dec 2024; status: terminated.
02
Drugs
vevoctadekin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06588660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588660.